Nivolumab + Relatlimab trials for Melanoma

All Nivolumab + Relatlimab trials · All Melanoma trials

Phase breakdown

Recruiting trials studying Nivolumab + Relatlimab for Melanoma

• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  NCT06112314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 211 locations
• Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
  NCT05428007 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 4 locations
• Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
  NCT04697576 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
  NCT06295159 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
  NCT06264180 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 81 locations

Common questions

How many trials study Nivolumab + Relatlimab for Melanoma?

5 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.